About US
Contact us
-
Generic floodgates open for Plavix in U.S.Plavix is a blood thinner from Bristol-Myers Squibb ($BMY). Generic Plavix is a Bristol-Myers profits thinner that is going to be produced by just about everybody and their brother. The FDA on Thursd2012/5/18
-
HGS puts 'poison pill' in its arsenal against GSKHuman Genome Sciences ($HGSI) has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline ($GSK). The company says the shareholder-ri2012/5/18
-
NIH taps Genentech drug for pioneering Alzheimer's studyThe NIH will help fund a landmark, $100 million study of Genentech's experimental Alzheimer's treatment crenezumab. Researchers will test the drug in Colombians with a particular genetic mutation, aim2012/5/17
-
Pennsylvania still trying get a slice of J&J Risperdal payoutsAn appeal being heard today on a case seen as the precursor to the mountains of litigation over Johnson & Johnson's ($JNJ) Risperdal may decide whether Pennsylvania will see any of the millions of2012/5/17
-
New discount persuades NICE to bless J&J's ZytigaZytiga will get a green light for U.K. patients after all. Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson ($JNJ) prostate cancer pill, thanks to the comp2012/5/16
-
Top 10 Best-selling Cancer Drugs in 2011Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development, as the upcoming American Society of Clinical Oncology mee2012/5/16
-
Shantha gets go-ahead for operational revampSanofi's ($SNY) plan for revamping Shantha Biotech won Indian government approval, clearing the way for it to recapture WHO contracts for its Shan5 vaccine. The health agency barred Shan5 in 2010 afte2012/5/15
-
Servier, founder face trial on Mediator chargesFrance's Mediator scandal has hit the courtroom. The drug's maker, Servier, and its founder are on trial in Nanterre, accused of misleading patients and regulators about the diabetes drug, often pr2012/5/15
-
India's drug regulator says it will clean up its actIndia's health agency has vowed that its top drug regulator will clean up its act, saying it will cinch up oversight rules for letting drugs on the market. Today's announcement comes a couple of days2012/5/14
-
FDA review questions long-term use of bone-building drugsThe FDA is giving women a lot to chew on with a new analysis of long-term use of drugs for osteoporosis because they can, although rarely, have a debilitating effect. The review was published Wedn2012/5/14